|
|
From the Leader's Desk
As we begin the new year, I am excited to share Syngene's new initiatives and achievements in supporting clients.
Firstly, we have rebranded our Research Informatics unit as Computational & Data Sciences. The new computational tools and capabilities we have added will help clients get from Data to Decisions faster. You can also read about our new Catalyst Screening Facility that supports high throughput screening reactions during drug discovery.
In keeping with our commitment to advancing science, our scientists supported a client in developing a biparatopic antibody to treat neurodegenerative and metabolic disorders related to NAD+ deficiency. Please read about this study published in the scientific journal 'mAbs'. Also included is a case study on how Syngene delivered pre-IND to IND Safety Studies for a leading biotech company in just three months.
Lastly, please consider this as my personal invitation to attend our upcoming scientific symposium, 'Faster, Stronger, Higher!' in Boston, on the role of artificial intelligence and machine learning in therapeutic discovery and early development. We plan to organize more such symposia in major scientific hubs and hope to be in your region soon!
Happy reading! |
|
|
Best Wishes, Kenneth J. Barr, Ph.D. Senior Vice President, Discovery Services Syngene International Ltd. |
|
|
In the Spotlight |
|
Computational & Data Sciences solutions: Enabling data-driven R&D for faster and cost-effective drug discovery |
|
Syngene offers a host of computational tools, including proprietary SARchitectTM (QSAR modelling) and Syn.AITM (artificial intelligence) solutions to help resolve complex scientific problems across target identification, hit identification, lead optimization, and translational research. Our capabilities extend across discovery biology (computational biology), discovery chemistry (computational chemistry), clinical development, and safety assessment. |
|
|
New at Syngene |
|
Catalyst Screening Facility |
|
Syngene's in-house dedicated Catalyst Screening Facility enables rapid go/no-go scientific decisions, reducing project duration by 2-3 weeks. The facility supports high-throughput screening reactions with state-of-the-art infrastructure. It provides for two kinds of chemical reactions - transition metal-catalyzed cross-coupling reactions and challenging acid-amine coupling, reductive alkylation reactions. |
|
|
|
|
Case Study |
|
How Syngene delivered pre-IND to IND Safety studies for a leading biotech company in just three months |
|
A biotech company had generated a strong pipeline of candidates for gut-brain diseases. Syngene's Safety team partnered with the company for multiple exploratory toxicity studies, four IND-enabling safety tox studies, and three 90-day toxicity studies in rodent species. As a result, the biotech company's Safety programs advanced from pre-IND to IND in just three months. |
|
|
Scientific Paper |
|
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity |
|
CD38 is an ecto-enzyme that metabolizes NAD+ and causes metabolic and inflammatory diseases, aging, and neurodegenerative disorders. Syngene scientists worked with a client to elucidate the crystal structure of TNB-738 - an anti-CD38 biparatopic antibody that can bind and inhibit the enzymatic activity of CD38. This presents an opportunity for a novel therapy to treat NAD+ disorders. |
|
|
|
|
Upcoming Events |
|
Faster, Stronger, Higher! |
|
AI and ML in early therapeutic discovery |
|
A scientific symposium where we bring experts in AI, ML and drug discovery to share their thoughts about the recent developments in the field and the future possibilities. If you are in Boston on 9th February, we would love to see you! |
|
Venue - Massachusetts Biotechnology Council, 700 Technology Square, Cambridge, MA 02139 Date & Time - 9th Feb 2023, 1 PM - 5 PM (EST) |
|
© 2023, Syngene International Ltd. Syngene International Ltd. Biocon Park, SEZ, Bommasandra Industrial Area - Phase-IV Bangalore 560099 India |